Exclusive Summary

• - Off‑patent legacy product registered in the US, enabling fast multi‑country roll‑out via a US‑CTD dossier for distribution.
• - Addresses high‑frequency needs in intraoperative and obstetric hypotension, aligned with ~330M surgeries and ~30M C‑sections per year worldwide.
• - Recommended as first‑line for spinal anesthesia–induced hypotension in obstetric guidelines, with clearer benefits versus ephedrine.
• - 10 mg/mL in 1/5/10 mL vials fits bolus and infusion preparation, minimizing wastage and standardizing OR workflows.
• - US compliance and dossier support hospital tenders, with meaningful per‑mg cost advantages versus branded/RTU premixes and opportunities during shortages.